CARDIFF ONCOLOGY INC

CRDFNASDAQ

🏆 #4134 by market capUS Equity

$456.86▲ $9.59 (+2.10%)

Simulated price

🔔

Track CRDF

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 2.1%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$93M

Small Cap

📈Revenue Growth (YoY)

-7.0%

Declining

📊Gross Margin

100.0%

High

💵FCF Margin

—

⚖️P/S Ratio

183.8x

Expensive

Otter Score

Weak

No chart data available for CRDF.

Trading Snapshot

Day Range: $453.57 – $459.07
52-Week Range: $0.76 – $3.31
Volume: $2.52B
Avg Volume: $2.74B
Shares Outstanding: 77.8M
Next Earnings: Nov 13, 2026

Fundamentals Snapshot

Annual Revenue: $593,000
Last Q Revenue: $104,000
P/E Ratio: —
P/S Ratio: 183.8x
EPS (TTM): $-0.59
Dividend Yield: —
Dilution (1yr): +40.3%

Why Investors Own CRDF

✓High-growth profile — revenue up +43.8% YoY with expanding US Equity exposure.
✓Healthy economics — 62% gross margin and 5% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CARDIFF ONCOLOGY INC

CRDF

Financial Trends

Revenue

$593K▼ −13.2% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

−$49M▲ +0.6% YoY

Free Cash Flow

−$38M▲ +0.5% YoY

Shares Outstanding

66.8M▲ +40.3% YoY

Net Cash

$17M▼ −$33M YoY

StockOtter · stockotter.space

About CARDIFF ONCOLOGY INC

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

🦦